KDL(SH:603987) Sou Hu Cai Jing·2025-06-24 13:05Company Overview - Kangdelai's closing price on June 24 was 7.5 yuan, with an increase of 2.46%, resulting in a rolling PE ratio of 15.20 times and a total market capitalization of 3.276 billion yuan [1] - The company operates in the medical device industry, focusing on the research, production, sales, and service of medical devices such as puncture needles and infusion devices [1] - Kangdelai ranks 35th in the industry based on PE ratio, with the industry average at 49.12 times and the median at 36.07 times [2] Financial Performance - For Q1 2025, Kangdelai reported revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.7042 million yuan, reflecting a slight increase of 0.28% [1] - The company's gross profit margin stood at 32.02% [1] Shareholder Information - As of March 31, 2025, Kangdelai had 25,817 shareholders, a decrease of 822 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Research and Development - The company has established a municipal-level enterprise technology center in Shanghai and has set up a provincial research institute for puncture medical devices in Zhejiang [1] - The R&D center of its subsidiary, Guangdong Medical Device Group, is recognized as a provincial engineering technology research center for puncture medical devices [1]